Brilinta, Growing Diabetes Line-Up Spotlighted By New AstraZeneca CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth potential for AstraZeneca's new cardiovascular drug Brilinta and its diabetes franchise were highlighted by the group’s new CEO Pacal Soriot during a third-quarter analysts' call but further details of his strategic thinking must wait at least until the end of January 2013.